XTALPI (02228) Partners with LABORATOIRES PIERRE FABRE on AI-Driven Drug Discovery Collaboration

XTALPI (02228) announced that QuantumPharm Limited and XtalPi Intelligent Drug Technology (Shanghai) Co., Ltd. (both wholly-owned subsidiaries of the Company) and Pierre Fabre Mdicament SAS (a member company of the Laboratoires Pierre Fabre group, "Laboratoires Pierre Fabre") have entered into a research collaboration agreement (the "Collaboration"), pursuant to which the Group and Laboratoires Pierre Fabre will collaborate on novel clinical candidate drug discovery across multiple research programs in the field of oncology, and may cover the fields of dermatology and rare diseases. Under the Collaboration, the Group will apply its integrated AI capabilities and Siasun Robot&Automation platform to de novo design and deliver novel small molecule therapeutics against undisclosed targets. Laboratoires Pierre Fabre will contribute its expertise in disease biology, drug discovery, translational research and clinical development to select and advance the most promising compounds, and will be responsible for subsequent clinical and commercial development. The Collaboration reflects the shared interest of both parties in exploring challenging and historically undruggable targets, an area with substantial unmet medical needs and significant opportunities in innovative drug discovery. Through this Collaboration, both parties aim to accelerate the identification of high-quality clinical candidates across multiple research programs in oncology and other potential therapeutic areas. The Collaboration includes an upfront payment, multiple milestone payments and subsequent economic sharing. The Board believes that the Collaboration advances the Group's work in applying AI and Siasun Robot&Automation technologies to de novo drug discovery, consolidates the Group's position in the field of AI- and Siasun Robot&Automation-driven drug discovery, and is in the overall interests of the Company and its shareholders.